Date: 2017-04-26
Type of information: Nomination
Compound:
Company: Sage Therapeutics (USA - MA)
Therapeutic area: CNS diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On April 26, 2017, Sage Therapeutics announced the appointment of Michael Cloonan as Chief Business Officer.
Michael Cloonan will lead Sage's Commercial, Portfolio and Program Management, Medical Affairs, and Corporate Development departments. Mr. Cloonan comes to Sage from Biogen, where he worked for 14 years. At Biogen, Mr. Cloonan most recently served as Senior Vice President, US Commercial, where he led a US affiliate with direct general manager responsibility for Sales, Marketing, Market Access, Patient Services and Commercial Operations. Previously, he held roles of increasing responsibility at Biogen, including Senior Vice President, Global Commercial Strategy; Vice President, Managing Director, Australia / New Zealand affiliate; and Vice President, Business Planning. Prior to Biogen, Mr. Cloonan worked at Bain & Company as a consultant specializing in healthcare. Mr. Cloonan received his M.B.A. from Darden Graduate School of Business Administration , University of Virginia and a B.A. from College of the Holy Cross .
Financial terms:
Latest news:
Is general: Yes
